pharma · Osteoarthritis of the Knee · Multiple Sclerosis · APUS
Apimeds Pharmaceuticals US
Apimeds Pharmaceuticals US patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Matawan, USA HQ
2020 Founded
3 Employees
Public company Type
APUS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Matawan, USA
- Founded
- 2020
- Employees
- 3
- Programs
- 3
- Drugs
- 2
- Patents
- 0
Apimeds Pharmaceuticals US patents
0 pharmaceutical patents indexed for Apimeds Pharmaceuticals US. 0 expire within 24 months.
Apimeds Pharmaceuticals US has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Apimeds Pharmaceuticals US have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Apimeds Pharmaceuticals US patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.